A study of mechanisms of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant NSCLC identified on next generation sequencing (NGS) from tumor tissue, presented at ASCO 2019, reported that resistance mechanisms to initial and later-line osimertinib are distinct from each other (33). This evidence concerns the gene EGFR and neoplasm.